Alexion to Present at the 14th Annual Citi Biotech Conference
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall Street futures fall as oil, Treasury yields rise on Iran tensions
- Oil prices steady as traders weigh supply risks
- Dell again lifts annual forecasts as AI demand powers record results
- Uber stock gains 2% as tech giant cuts 3,300 jobs in major restructuring
- Berkshire’s Abel says data centers are energy opportunity
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Gap taps Coach architect Reed Krakoff for $29.95-$498 handbag line
- S&P Global shares rise on report of possible CapIQ spinoff
Stifel Reiterates Hold Rating on Alexion Pharmaceuticals (ALXN)
August 30, 2019 12:14 PM EDTStifel analyst Paul Matteis reiterated a Hold rating and {REMOVEPT} price target on Alexion Pharmaceuticals (NASDAQ: ALXN)
The analyst comments "While the implications of a theoretical Soliris biosimilar launch (assuming ALXN converts) remain debatable, we expect the IPR institution decision this morning... More
Citi Is Buyer on Weakness in Alexion Pharmaceuticals (ALXN), Sees Fair Value around $131-$133
August 30, 2019 12:00 PM EDTCiti analyst Mohit Bansal reiterated a Buy rating and $150.00 price target on Alexion Pharmaceuticals (NASDAQ: ALXN).
Analyst is buyer on weakness.Sees FV around $131 to $133 per share.Says while weakness is justified, there is still value in the... More